Figure 3.
Comparison of Exo-DOX formulations on cancer cell proliferation and apoptosis.
Notes: (A) The IC50 of free DOX in PCCs was determined after treatment with indicated concentrations for 24, 48, and 72 h. PCCs were treated with Exo-DOX (B) or Exos (C) obtained from PCCs, PSCs, and MØs for 24, 48, and 72 h, and viability of cells was determined by the WST-1 assay. Data expressed as mean ± SD (n=3), *P<0.05.
Abbreviations: DOX, doxorubicin; Exos, exosomes; MØs, macrophages; PCCs, pancreatic cancer cells; PSCs, pancreatic stellate cells; CTRL, control.